A carregar...
Epoprostenol sodium for treatment of pulmonary arterial hypertension
The release of endogenous prostacyclin (PGI(2)) is depressed in patients with pulmonary arterial hypertension (PAH). PGI(2) replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epopro...
Na minha lista:
| Publicado no: | Vasc Health Risk Manag |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4437604/ https://ncbi.nlm.nih.gov/pubmed/25999730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S50368 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|